Diel IJ - Search Results

1

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review.

Diel IJ. Diel IJ. Support Care Cancer. 2007 Nov;15(11):1243. doi: 10.1007/s00520-007-0244-9. Epub 2007 Mar 29. Support Care Cancer. 2007. PMID: 17393190 Review.

2

Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.

Diel IJ, Kurth AH, Sittig HB, Meden H, Maasberg M, Sandermann A, Bergner R. Diel IJ, et al. Support Care Cancer. 2010 Oct;18(10):1305-12. doi: 10.1007/s00520-009-0749-5. Epub 2010 Feb 12. Support Care Cancer. 2010. PMID: 20151162

3

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.

Diel I, Ansorge S, Hohmann D, Giannopoulou C, Niepel D, Intorcia M. Diel I, et al. Support Care Cancer. 2020 Nov;28(11):5223-5233. doi: 10.1007/s00520-020-05357-5. Epub 2020 Feb 21. Support Care Cancer. 2020. PMID: 32086567 Free PMC article.

4

Adverse effects of bisphosphonates: current issues.

Diel IJ, Bergner R, Grötz KA. Diel IJ, et al. J Support Oncol. 2007 Nov-Dec;5(10):475-82. J Support Oncol. 2007. PMID: 18240669 Review.

5

Treatment of metastatic bone disease in breast cancer: bisphosphonates.

Diel IJ, Solomayer EF, Bastert G. Diel IJ, et al. Clin Breast Cancer. 2000 Apr;1(1):43-51. doi: 10.3816/CBC.2000.n.003. Clin Breast Cancer. 2000. PMID: 11899389 Review.

6

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF 4265 Study Group. Diel IJ, et al. Eur J Cancer. 2004 Jul;40(11):1704-12. doi: 10.1016/j.ejca.2004.03.025. Eur J Cancer. 2004. PMID: 15251160 Clinical Trial.

7

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Stopeck AT, et al. Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Support Care Cancer. 2016. PMID: 26335402 Free PMC article. Clinical Trial.

8

Ibandronate: efficacy in the treatment of metastatic bone disease.

Diel IJ. Diel IJ. Future Oncol. 2005 Oct;1(5):593-607. doi: 10.2217/14796694.1.5.593. Future Oncol. 2005. PMID: 16556036 Review.

9

Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.

Link H, Diel I, Ohlmann CH, Holtmann L, Kerkmann M; Associations Supportive Care in Oncology (AGSMO), Medical Oncology (AIO), Urological Oncology (AUO), within the German Cancer Society (DKG) and the German Osteooncological Society (DOG). Link H, et al. Support Care Cancer. 2020 May;28(5):2175-2184. doi: 10.1007/s00520-019-05018-2. Epub 2019 Aug 14. Support Care Cancer. 2020. PMID: 31410600 Free PMC article.

10

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.

Pecherstorfer M, Diel IJ. Pecherstorfer M, et al. Among authors: diel ij. Support Care Cancer. 2004 Dec;12(12):877-81. doi: 10.1007/s00520-004-0655-9. Epub 2004 Sep 15. Support Care Cancer. 2004. PMID: 15372222 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page